Latest Insider Transactions at Novo Cure LTD (NVCR)
This section provides a real-time view of insider transactions for Novo Cure LTD (NVCR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NovoCure Ltd to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NovoCure Ltd's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 03
2022
|
Ashley Cordova Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,040
+3.7%
|
$65,520
$13.53 P/Share
|
|
Mar 03
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
930
-0.89%
|
$68,820
$74.5 P/Share
|
|
Mar 03
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
17,371
+14.25%
|
-
|
|
Mar 03
2022
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,301
-0.76%
|
$96,274
$74.5 P/Share
|
|
Mar 03
2022
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,921
+11.31%
|
-
|
|
Mar 03
2022
|
William Patrick Burke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
341
-0.58%
|
$25,234
$74.5 P/Share
|
|
Mar 03
2022
|
William Patrick Burke Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,445
+11.31%
|
-
|
|
Mar 03
2022
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
803
-1.76%
|
$59,422
$74.5 P/Share
|
|
Mar 03
2022
|
Ely Benaim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,371
+27.6%
|
-
|
|
Mar 03
2022
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
997
-1.05%
|
$73,778
$74.5 P/Share
|
|
Mar 03
2022
|
Pritesh Shah Chief Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,714
+18.57%
|
-
|
|
Mar 03
2022
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,371
+26.1%
|
-
|
|
Mar 03
2022
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,149
-1.81%
|
$85,026
$74.5 P/Share
|
|
Mar 03
2022
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,508
+25.36%
|
-
|
|
Mar 03
2022
|
Todd Christopher Longsworth General Counsel |
SELL
Open market or private sale
|
Direct |
1,094
-1.61%
|
$80,956
$74.5 P/Share
|
|
Jan 06
2022
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75
+0.05%
|
$4,725
$63.82 P/Share
|
|
Jan 06
2022
|
Asaf Danziger Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31
+0.23%
|
$1,953
$63.82 P/Share
|
|
Jan 06
2022
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46
+0.11%
|
$2,898
$63.82 P/Share
|
|
Jan 06
2022
|
Ely Benaim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55
+0.19%
|
$3,465
$63.82 P/Share
|
|
Jan 06
2022
|
William Patrick Burke Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80
+0.16%
|
$5,040
$63.82 P/Share
|
|
Jan 06
2022
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35
+0.11%
|
$2,205
$63.82 P/Share
|
|
Jan 03
2022
|
William Patrick Burke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
3,951
-2.87%
|
$300,276
$76.03 P/Share
|
|
Jan 03
2022
|
William Patrick Burke Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,604
+15.77%
|
$371,852
$13.4 P/Share
|
|
Nov 26
2021
|
Asaf Danziger Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
4,974
+10.65%
|
$497,400
$100.74 P/Share
|
|
Nov 02
2021
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
209
-0.5%
|
$22,363
$107.28 P/Share
|
|
Sep 03
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
501
-0.23%
|
$69,639
$139.23 P/Share
|
|
Sep 02
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
156
-0.21%
|
$21,528
$138.23 P/Share
|
|
Sep 02
2021
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
181
-0.12%
|
$24,978
$138.23 P/Share
|
|
Sep 02
2021
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
828
-1.93%
|
$114,264
$138.23 P/Share
|
|
Sep 02
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
540
-0.62%
|
$74,520
$138.23 P/Share
|
|
Aug 12
2021
|
Ashley Cordova Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
1,733
-3.77%
|
-
|
|
Aug 12
2021
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
26,624
-10.2%
|
$3,727,360
$140.93 P/Share
|
|
Aug 12
2021
|
Ashley Cordova Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,624
+10.59%
|
$1,245,216
$34.13 P/Share
|
|
Aug 05
2021
|
Gabriel Leung |
SELL
Open market or private sale
|
Direct |
1,000
-1.35%
|
$152,000
$152.5 P/Share
|
|
Aug 05
2021
|
Gabriel Leung |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.34%
|
$31,000
$31.45 P/Share
|
|
Aug 05
2021
|
Martin J. Madden |
SELL
Open market or private sale
|
Indirect |
34
-8.13%
|
$5,202
$153.13 P/Share
|
|
Aug 04
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
2,063
-2.71%
|
$305,324
$148.71 P/Share
|
|
Aug 03
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
464
-1.62%
|
$69,600
$150.11 P/Share
|
|
Aug 03
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
1,654
-2.12%
|
$246,446
$149.43 P/Share
|
|
Aug 03
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
328
-0.37%
|
$48,872
$149.43 P/Share
|
|
Aug 02
2021
|
William F Doyle Executive Chairman |
SELL
Open market or private sale
|
Direct |
995
-0.18%
|
$148,255
$149.38 P/Share
|
|
Aug 02
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
713
-0.79%
|
$106,237
$149.38 P/Share
|
|
Aug 02
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
536
-1.84%
|
$79,864
$149.38 P/Share
|
|
Jul 31
2021
|
Pritesh Shah Chief Growth Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,717
+4.16%
|
$572,418
$154.01 P/Share
|
|
Jul 30
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
651
-2.18%
|
$102,858
$158.96 P/Share
|
|
Jul 30
2021
|
Ely Benaim Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
651
+2.14%
|
$54,033
$83.3 P/Share
|
|
Jul 06
2021
|
Gabriel Leung |
SELL
Open market or private sale
|
Direct |
1,000
-1.35%
|
$183,000
$183.54 P/Share
|
|
Jul 06
2021
|
Gabriel Leung |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.34%
|
$31,000
$31.45 P/Share
|
|
Jul 06
2021
|
Todd Christopher Longsworth General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
154
+0.23%
|
$21,098
$137.12 P/Share
|
|
Jul 06
2021
|
Pritesh Shah Chief Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
154
+0.2%
|
$21,098
$137.12 P/Share
|